Want to see AU:MVP full AI Analyst Report?
MVP Stock Chart & Stats
AU$0.46
-AU$0.02(-4.00%)
At close: 4:00 PM EDT
AU$0.46
-AU$0.02(-4.00%)
Day’s Range― - ―
52-Week RangeAU$0.37 - AU$0.75
Previous CloseN/A
Volume529.07K
Average Volume (3M)143.92K
Market Cap
AU$45.63M
Enterprise ValueAU$26.09M
Total Cash (Recent Filing)AU$21.37M
Total Debt (Recent Filing)AU$1.67M
Price to Earnings (P/E)72.3
Beta1.42
Next Earnings
Feb 25, 2027EPS Estimate
0.02Next Dividend Ex-DateN/A
Dividend Yield0.49%
Share Statistics
EPS (TTM)<0.01
Shares Outstanding112,658,325
10 Day Avg. Volume182,442
30 Day Avg. Volume143,924
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)0.80
Price to Sales (P/S)1.05
P/FCF Ratio8.45
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$1.00Price Target Upside117.39% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.01
Revenue Forecast (FY)AU$45.95M
Bulls Say, Bears Say
Bulls Say
Pain Management GrowthStrong growth in the core Pain Management segment indicates expanding demand across both European and Australian markets. Higher volumes and improved segment EBIT provide a stronger foundation for sustained revenue growth, investment in expansion, and improved operating leverage.
Penthrox Market ExpansionThe expanded European pediatric indication broadens Penthrox’s addressable patient population, while published clinical and economic evidence can support adoption by healthcare providers. These regulatory and evidence milestones strengthen the product’s commercial platform beyond short-term sales effects.
Balance Sheet And Cash StrengthVery low leverage and substantial cash provide financial flexibility to fund targeted geographic and indication expansion without relying heavily on external financing. The conservative balance sheet also improves resilience while the company develops growth opportunities and manages operating volatility.
Bears Say
Thin And Volatile ProfitabilityAlthough profitability has recovered, the small net margin leaves limited room for execution errors, cost increases, or weaker demand to reduce earnings. The history of severe losses and near-break-even results also shows that sustainable profit generation remains unproven.
Respiratory Segment DeclineWeakness in Respiratory offsets the company’s Pain Management momentum and reduces the contribution from a second product platform. Continued softness, especially in the U.S., could constrain consolidated growth and make overall performance more dependent on Penthrox.
Mature Australian Ambulance ChannelHigh penetration in the foundational Australian ambulance channel limits the scope for rapid incremental volume from an established market. Future Penthrox growth therefore depends more heavily on hospital adoption and new geographies, which may require longer commercialization cycles.
Medical Developments International Limited News
MVP FAQ
What was Medical Developments International Limited’s price range in the past 12 months?
Medical Developments International Limited lowest share price was AU$0.36 and its highest was AU$0.74 in the past 12 months.
What is Medical Developments International Limited’s market cap?
Medical Developments International Limited’s market cap is AU$45.63M.
When is Medical Developments International Limited’s upcoming earnings report date?
Medical Developments International Limited’s upcoming earnings report date is Feb 25, 2027 which is in 126 days.
How were Medical Developments International Limited’s earnings last quarter?
Medical Developments International Limited released its earnings results on Aug 19, 2026. The company reported AU$0.007 earnings per share for the quarter, beating the consensus estimate of -AU$0.006 by AU$0.013.
Is Medical Developments International Limited overvalued?
According to Wall Street analysts Medical Developments International Limited’s price is currently Undervalued.
Does Medical Developments International Limited pay dividends?
Medical Developments International Limited pays a Semiannually dividend of AU$0.019 which represents an annual dividend yield of 0.49%. See more information on Medical Developments International Limited dividends here
What is Medical Developments International Limited’s EPS estimate?
Medical Developments International Limited’s EPS estimate is 0.02.
How many shares outstanding does Medical Developments International Limited have?
Medical Developments International Limited has 112,658,325 shares outstanding.
What happened to Medical Developments International Limited’s price movement after its last earnings report?
Medical Developments International Limited reported an EPS of AU$0.007 in its last earnings report, beating expectations of -AU$0.006. Following the earnings report the stock price went down -7.767%.
Which hedge fund is a major shareholder of Medical Developments International Limited?
Currently, no hedge funds are holding shares in AU:MVP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Medical Developments International Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$1.00 (117.39% Upside)
AU$1.00 (117.39% Upside)
Blogger Sentiment
Bullish
AU:MVP Sentiment 100%
Sector Average 67%
Sector Average 67%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-42.85%
12-Months-Change
Fundamentals
Return on Equity
1.13%
Trailing 12-Months
Asset Growth
-3.03%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Medical Developments International Limited
Medical Developments International Limited (MDIL) specializes in the development and provision of essential emergency medical solutions, serving global markets including Australia, Europe, and the United States. The company's operations are divided into two primary segments: Pain Management and Respiratory care. Among its key offerings is Penthrox, a product specifically formulated for rapid pain relief in acute trauma and emergency situations. Within the respiratory segment, MDIL supplies equipment designed to assist individuals with conditions like asthma and chronic obstructive pulmonary disease (COPD). Additionally, its comprehensive portfolio features a diverse array of medical devices, encompassing items such as CPR face shields and masks, finger pulse oximeters, flow meter regulators, MDI tourniquets, manually triggered ventilators, oxygen resuscitation kits, and various oxygen therapy and resuscitation apparatus. Established in 2003, the company maintains its headquarters in Scoresby, Australia.
MVP Stock 12 Month Forecast
Average Price Target
AU$1.00
▲(117.39% Upside)
Technical Analysis
Cann Group
―
Epsilon Healthcare Limited
―
Little Green Pharma Ltd.
―
Althea Group Holdings Ltd.
―
Cronos Australia Ltd.
―